The Argentina pharmaceutical market size reached USD 11.52 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 21.46 Billion by 2033, exhibiting a growth rate (CAGR) of 6.42% during 2025-2033. The market is driven by regulatory modernization and the rapid expansion of the biosimilar segment, enhancing accessibility and competitive dynamics. Advancements in mRNA technology transfer and the development of robust manufacturing infrastructure are strengthening production capabilities. Additionally, economic pressures are prompting market consolidation and fostering innovation, reshaping the pharmaceutical landscape. These combined factors are opening new avenues for growth, regional collaboration, and strategic investments, collectively contributing to the expansion of the Argentina pharmaceutical market share.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 11.52 Billion |
Market Forecast in 2033 | USD 21.46 Billion |
Market Growth Rate 2025-2033 | 6.42% |
Regulatory Modernization and Biosimilar Market Expansion
Argentina's pharmaceutical regulatory framework has undergone significant modernization, with ANMAT (National Administration of Drugs, Food and Medical Technology) implementing enhanced biosimilar regulations and streamlined approval processes. The measures introduced through Decree 1741/2025 represent an important step toward a more inclusive and sustainable healthcare system in the country, with 28 biosimilars authorized to date, highlighting the maturity of the regulatory system. This regulatory advancement positions Argentina as a regional leader in biosimilar development and manufacturing. The country has developed specific regulations including Reg. 7729/11 for biosimilar registration requirements and the recent Reg. 741/2025 defining comparability criteria. This regulatory evolution supports domestic production capabilities while ensuring international compliance standards, making Argentina an attractive destination for pharmaceutical investment and regional manufacturing hubs.
mRNA Technology Transfer and Manufacturing Infrastructure Development
Argentina has emerged as a key player in regional mRNA vaccine production through strategic partnerships with international organizations. In September 2021, PAHO announced that Sinergium Biotech, in Argentina, and the Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), in Brazil, were selected for technology transfer under an international cooperation initiative. This initiative represents a fundamental shift toward regional pharmaceutical self-sufficiency and pandemic preparedness. The mRNA technology transfer program involves collaboration between WHO, PAHO, and the Medicines Patent Pool to establish sustainable vaccine production capabilities. Argentina's participation in this program strengthens its biotechnology infrastructure and positions the country as a strategic supplier for the region, reducing dependence on imports during health emergencies and fostering technological innovation, boosting Argentina pharmaceutical market growth.
Economic Pressures Driving Market Consolidation and Innovation
The Argentine pharmaceutical market has experienced significant economic pressures, including currency devaluation and pricing challenges that are reshaping industry dynamics. Data from the Argentine Confederation of Medium-Sized Enterprises shows that pharmacy sales dropped 39% year-on-year at constant prices and are down 42% in the first two months of 2024, reflecting broader economic challenges facing the healthcare sector. Despite these challenges, the market is adapting through increased focus on local production, generic drug development, and biosimilar manufacturing. This economic environment is driving pharmaceutical companies to pursue more efficient operations, strategic partnerships, and innovative business models. The pressure is also accelerating adoption of cost-effective manufacturing technologies and promoting regional collaboration to reduce dependency on expensive imported pharmaceuticals while maintaining market competitiveness and ensuring continued access to essential medicines, highlighting key Argentina pharmaceutical market trends.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on type and nature.
Type Insights:
A detailed breakup and analysis of the market based on type have also been provided in the report. This includes pharmaceutical drugs (cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal disorder drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs) and biologics (monoclonal antibodies (MAbS), therapeutic proteins, and vaccines).
Nature Insights:
The report has provided a detailed breakup and analysis of the market based on nature. This includes organic and conventional.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Buenos Aires Region, Litoral Region, Northern Region, Cordoba Region, Cuyo Region, and Patagonia Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Modalities Covered |
|
Natures Covered | Organic, Conventional |
Regions Covered | Buenos Aires Region, Litoral Region, Northern Region, Cordoba Region, Cuyo Region, Patagonia Region |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: